Spyre Therapeutics (NASDAQ: SYRE) revenue
Spyre Therapeutics reported revenue of $0.0m for fiscal 2025; in fiscal 2024 it was $0.0m.
Spyre Therapeutics's best year of the last 10 was fiscal 2021. The biggest drop was in fiscal 2022, −87.6%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $0.0m | — | −$209.6m | — |
| 2024 | $0.0m | −100.0% | −$208.6m | — |
| 2023 | $0.9m | −62.0% | −$242.3m | −27,348.0% |
| 2022 | $2.3m | −87.6% | −$84.8m | −3,640.2% |
| 2021 | $18.7m | — | −$65.6m | −350.3% |
| 2020 | $0.0m | — | −$81.5m | — |
| 2019 | $0.0m | −100.0% | −$80.3m | — |
| 2018 | $3.9m | −25.3% | −$45.5m | −1,169.3% |
| 2017 | $5.2m | +12.5% | −$27.7m | −531.7% |
| 2016 | $4.6m | — | −$21.9m | −473.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Spyre Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Spyre Therapeutics ranks 420th of the 422 US health care companies with a page on Celsmar.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 418th | Spruce Biosciences | $0.0m | −100.0% |
| 419th | Scholar Rock | $0.0m | — |
| 420th | Spyre Therapeutics | $0.0m | — |
| 421st | Tenax Therapeutics | $0.0m | — |
| 422nd | Zentalis Pharmaceuticals | $0.0m | −100.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Spyre Therapeutics
- How much revenue did Spyre Therapeutics make in fiscal 2025?
- Spyre Therapeutics reported revenue of $0.0m for fiscal 2025, compared with $0.0m in fiscal 2024.
- What was the best year for revenue at Spyre Therapeutics?
- Of its last 10 fiscal years, fiscal 2021, with $18.7m.
- Where does Spyre Therapeutics rank in its sector by revenue?
- It ranks 420th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Spyre Therapeutics come from?
- From the annual report (Form 10-K) that Spyre Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Spyre Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Spyre Therapeutics: the Spyre Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.